← back to search

James N’Dow

University of Aberdeen · GB
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Pelvic floor disorders treatments, Urinary Bladder and Prostate Research, and Prostate Cancer Diagnosis and Treatment.
h-index
36
citations
6,761
works
161
NIH funding
primary concept
Medicine
email

Recent publications

Comparing the clinical and cost-effectiveness of various washout policies in preventing catheter associated complications in adults living with long-term catheters: synopsis of the CATHETER II RCT.
2026cited by 0position: contributordoi
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non–muscle-invasive Bladder Cancer
European Urology Oncology 2025cited by 9position: middledoi
Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review.
2025cited by 5position: contributordoi
PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research.
2025cited by 4position: contributordoi
AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium.
2025cited by 1position: contributordoi
Patient and healthcare professionals' perception of weekly prophylactic catheter washout in adults living with long-term catheters: qualitative study of the CATHETER II trial.
2025cited by 1position: contributordoi
Using Artificial Intelligence for Text Screening in a Systematic Review of Cardiotoxicity.
2025cited by 0position: contributordoi
Reply to: Rong Dai and Changkai Deng's Letter to the Editor re: Anirban Dey, Georgios Georgiadis, Justin Umezurike, et al. Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review. Eur Urol Focus. 2025;11:237-250. https://doi.org/10.1016/j.euf.2024.09.012.
2025cited by 0position: contributordoi
Real-world Evidence on Baseline Characteristics and Treatment in Metastatic Hormone-sensitive Prostate Cancer: Findings from the PIONEER 2.0 Big Data Investigation Group.
2025cited by 0position: contributordoi
The Lancet Commission on prostate cancer: planning for the surge in cases
The Lancet 2024cited by 607position: middledoi
The Lancet Commission on prostate cancer: planning for the surge in cases.
2024cited by 424position: contributordoi
From BPH to male LUTS: a 20-year journey of the EAU guidelines.
2024cited by 29position: contributordoi
Improving Patient Information and Enhanced Consent in Urology: The Impact of Simulation and Multimedia Tools. A Systematic Literature Review from the European Association of Urology Patient Office
European Urology 2024cited by 13position: middledoi
Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.
2024cited by 13position: contributordoi
ESRU-ESU-YAU_UROTECH Survey on Urology Residents Surgical Training: Are We Ready for Simulation and a Standardized Program?
2024cited by 9position: contributordoi
Improving Patient Information and Enhanced Consent in Urology: The Impact of Simulation and Multimedia Tools. A Systematic Literature Review from the European Association of Urology Patient Office.
2024cited by 7position: contributordoi
Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform.
2024cited by 3position: contributordoi
CATHETER II: a randomised controlled trial comparing the clinical effectiveness of various washout policies versus no washout policy in preventing catheter-associated complications in adults living with long-term catheters.
2024cited by 3position: contributordoi
Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review.
2024cited by 2position: contributordoi
Three-year cost utility analysis of mini versus standard slings: A trial based economic evaluation.
2024cited by 1position: contributordoi
Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer.
2024cited by 1position: contributordoi
Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
BJUI Compass 2024cited by 0position: middledoi
Specifying behavioural and strategy components of de-implementation efforts targeting low-value prescribing practices in secondary health care.
2024cited by 0position: contributordoi
How Can We Improve Patient-Clinician Communication for Men Diagnosed with Prostate Cancer?
2024cited by 0position: contributordoi
From BPH to male LUTS: a 20-year journey of the EAU guidelines
Prostate Cancer and Prostatic Diseases 2023cited by 42position: middledoi
Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum
European Urology Oncology 2023cited by 27position: middledoi
Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
2023cited by 17position: contributordoi
How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis.
2023cited by 10position: contributordoi
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
2023cited by 9position: contributordoi
Erratum to “European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel” [Eur. Urol. 79(4) (2021) 480–488]
European Urology 2023cited by 5position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Muhammad Imran Omar · University of Zakho25 papers (2019–2026)Maria J. Ribal · Hôpital de la Croix-Rousse21 papers (2020–2025)John Norrie · London School of Hygiene & Tropical Medicine13 papers (2019–2026)Juan Gómez Rivas · Erasmus University Rotterdam10 papers (2020–2025)Mieke Van Hemelrijck · Ghent University Hospital7 papers (2020–2022)Graeme MacLennan · University of Aberdeen6 papers (2020–2026) · 5 papers (2020–2026)Steven MacLennan · BMJ Publishing Group5 papers (2020–2024)Sara MacLennan · Innovative Medicines Initiative5 papers (2020–2026)Henkjan Huisman · B2 (Slovenia)4 papers (2020–2023)Monique J. Roobol · Centre Hospitalier Universitaire de Lille4 papers (2020–2025)Mary Kilonzo · University of Aberdeen4 papers (2022–2026)David Cooper · University of Aberdeen4 papers (2022–2026)Paul Little · The London College4 papers (2022–2026)Jeremy Yuen‐Chun Teoh · Gleneagles Hospital3 papers (2020–2024)Ann Henry · University of Leeds3 papers (2019–2021)Silke Gillessen · University Hospitals Seidman Cancer Center3 papers (2019–2021)Peter Murchie · University of Aberdeen3 papers (2024–2026)Catherine Paterson · Flinders University3 papers (2024–2026)James Larcombe · BMJ Publishing Group3 papers (2024–2026)